WEKO3
-
RootNode
アイテム
Combination Chemotherapy with Low-dose 5-FU, Cisplatin, and Gemcitabine for Gemcitabine-Refractory Pancreatic Cancer
http://hdl.handle.net/10091/3729
http://hdl.handle.net/10091/3729cd5dd989-99e5-46e2-b35c-dbfff0682311
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
Shinshu_Med57-6-03.pdf (929.2 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2009-12-15 | |||||||||||||||||
| タイトル | ||||||||||||||||||
| タイトル | Combination Chemotherapy with Low-dose 5-FU, Cisplatin, and Gemcitabine for Gemcitabine-Refractory Pancreatic Cancer | |||||||||||||||||
| 言語 | ||||||||||||||||||
| 言語 | eng | |||||||||||||||||
| DOI | ||||||||||||||||||
| 関連タイプ | isIdenticalTo | |||||||||||||||||
| 関連識別子 | https://doi.org/10.11441/shinshumedj.57.247 | |||||||||||||||||
| 関連名称 | 10.11441/shinshumedj.57.247 | |||||||||||||||||
| キーワード | ||||||||||||||||||
| 主題 | second-lin chemotherapy, pancreatic cancer, 5-FU, Cisplatin, Gemcitabine | |||||||||||||||||
| 資源タイプ | ||||||||||||||||||
| 資源 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||
| タイプ | journal article | |||||||||||||||||
| 著者 |
ARAKURA, Norikazu
× ARAKURA, Norikazu
× HASEBE, Osamu
× OCHI, Yasuhide
× HAMANO, Hideaki
× TANAKA, Eiji
× KAWA, Shigeyuki
|
|||||||||||||||||
| 信州大学研究者総覧へのリンク | ||||||||||||||||||
| 氏名 | TANAKA, Eiji | |||||||||||||||||
| URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.HFDCHekh.html | |||||||||||||||||
| 信州大学研究者総覧へのリンク | ||||||||||||||||||
| 氏名 | KAWA, Shigeyuki | |||||||||||||||||
| URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.jakeOVkh.html | |||||||||||||||||
| 出版者 | ||||||||||||||||||
| 出版者 | 信州医学会 | |||||||||||||||||
| 引用 | ||||||||||||||||||
| 内容記述 | 信州医学雑誌 57(6): 247-253(2009) | |||||||||||||||||
| 書誌情報 |
信州医学雑誌 巻 57, 号 6, p. 247-253, 発行日 2009-12-10 |
|||||||||||||||||
| 抄録 | ||||||||||||||||||
| 内容記述 | Background : No single agent or combination therapy for advanced pancreatic cancer has been reported superior to single-agent GEM, and an effective second-line chemotherapy option is needed for patients who are resistant to first-line GEM therapy. Methods :We analyzed six patients who had disease progression following first-line gemcitabine therapy. Patients received second-line chemotherapy with low dose cisplatin, 5-fluorouracul or S-1,and gemcitabine every 21 days. Results : Two patients showed a partial response (33.3%) and two showed stable disease. Four patients (66.6%) showed a prolonged survival time with partial responses or stable disease.Median survival times were 7 and 11 months from the start of second-line therapy and the start of first-line gemcitabine therapy,respectively. In addition, all patients reported relief from pain and had a favorable performance status. The major toxicities of leucopenia, stomatitis, and diarrhea were found in one patient each.Conclusion : This second-line chemotherapy regimen is an effective option for patients with gemcitabineresistant pancreatic cancer. | |||||||||||||||||
| 資源タイプ（コンテンツの種類） | ||||||||||||||||||
| ISSN | ||||||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||||||
| 収録物識別子 | 0037-3826 | |||||||||||||||||
| 書誌レコードID | ||||||||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||||||||
| 収録物識別子 | AN00120815 | |||||||||||||||||
| 出版タイプ | ||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||
Share
Cite as
ARAKURA, Norikazu, HASEBE, Osamu, OCHI, Yasuhide, HAMANO, Hideaki, TANAKA, Eiji, KAWA, Shigeyuki, 2009, Combination Chemotherapy with Low-dose 5-FU, Cisplatin, and Gemcitabine for Gemcitabine-Refractory Pancreatic Cancer: 信州医学会, 247–253 p.
Loading...
